Cargando…

COVID-19 seroprevalence in Pakistan: a cross-sectional study

OBJECTIVES: This study adapted WHO’s ‘Unity Study’ protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection. DESIGN: This population-based, age-stratified cross-sectional study was conducted at the level of households (HH). PARTI...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, Ahsan M, Shahzad, Khurram, Masood, Mariumn, Umar, Maida, Abbasi, Fahad, Hafeez, Assad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987211/
https://www.ncbi.nlm.nih.gov/pubmed/35387815
http://dx.doi.org/10.1136/bmjopen-2021-055381
_version_ 1784682690670231552
author Ahmad, Ahsan M
Shahzad, Khurram
Masood, Mariumn
Umar, Maida
Abbasi, Fahad
Hafeez, Assad
author_facet Ahmad, Ahsan M
Shahzad, Khurram
Masood, Mariumn
Umar, Maida
Abbasi, Fahad
Hafeez, Assad
author_sort Ahmad, Ahsan M
collection PubMed
description OBJECTIVES: This study adapted WHO’s ‘Unity Study’ protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection. DESIGN: This population-based, age-stratified cross-sectional study was conducted at the level of households (HH). PARTICIPANTS: All ages and genders were eligible for the study (exclusion criteria: contraindications to venipuncture- however, no such case was encountered). 4998 HH out of 6599 consented (1 individual per HH). The proportion of male and female study participants was similar. PRIMARY AND SECONDARY OUTCOME MEASURES: Following were the measured outcome measures- these were different from the planned indicators (i.e. two out of the three planned indicators were measured) due to operational reasons and time constraints: - Primary indicators: Seroprevalence (population and age specific). Secondary indicators: Population groups most at risk for SARS-CoV-2-infection. RESULTS: Overall seroprevalence of SARS-CoV-2 antibodies was 7.1%. 6.3% of individuals were IgG positive while IgM positivity was 1.9%. Seroprevalence in districts ranged from 0% (Ghotki) to 17% (Gilgit). The seroprevalence among different age groups ranged from 3.9% (0–9 years) to 10.1% (40–59 years). There were no significant differences in the overall seroprevalence for males and females. A history of contact with a confirmed COVID-19 case, urban residence and mask use were key risk factors for developing SARS-CoV-2 infection. CONCLUSIONS: This survey provides useful estimates for seroprevalence in the general population and information on risk factors for developing SARS-CoV-2 infection in the country. It is premised that similar studies need to be replicated at the population level on a regular basis to monitor the disease and immunity patterns related to COVID-19.
format Online
Article
Text
id pubmed-8987211
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89872112022-04-07 COVID-19 seroprevalence in Pakistan: a cross-sectional study Ahmad, Ahsan M Shahzad, Khurram Masood, Mariumn Umar, Maida Abbasi, Fahad Hafeez, Assad BMJ Open Epidemiology OBJECTIVES: This study adapted WHO’s ‘Unity Study’ protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection. DESIGN: This population-based, age-stratified cross-sectional study was conducted at the level of households (HH). PARTICIPANTS: All ages and genders were eligible for the study (exclusion criteria: contraindications to venipuncture- however, no such case was encountered). 4998 HH out of 6599 consented (1 individual per HH). The proportion of male and female study participants was similar. PRIMARY AND SECONDARY OUTCOME MEASURES: Following were the measured outcome measures- these were different from the planned indicators (i.e. two out of the three planned indicators were measured) due to operational reasons and time constraints: - Primary indicators: Seroprevalence (population and age specific). Secondary indicators: Population groups most at risk for SARS-CoV-2-infection. RESULTS: Overall seroprevalence of SARS-CoV-2 antibodies was 7.1%. 6.3% of individuals were IgG positive while IgM positivity was 1.9%. Seroprevalence in districts ranged from 0% (Ghotki) to 17% (Gilgit). The seroprevalence among different age groups ranged from 3.9% (0–9 years) to 10.1% (40–59 years). There were no significant differences in the overall seroprevalence for males and females. A history of contact with a confirmed COVID-19 case, urban residence and mask use were key risk factors for developing SARS-CoV-2 infection. CONCLUSIONS: This survey provides useful estimates for seroprevalence in the general population and information on risk factors for developing SARS-CoV-2 infection in the country. It is premised that similar studies need to be replicated at the population level on a regular basis to monitor the disease and immunity patterns related to COVID-19. BMJ Publishing Group 2022-04-06 /pmc/articles/PMC8987211/ /pubmed/35387815 http://dx.doi.org/10.1136/bmjopen-2021-055381 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Ahmad, Ahsan M
Shahzad, Khurram
Masood, Mariumn
Umar, Maida
Abbasi, Fahad
Hafeez, Assad
COVID-19 seroprevalence in Pakistan: a cross-sectional study
title COVID-19 seroprevalence in Pakistan: a cross-sectional study
title_full COVID-19 seroprevalence in Pakistan: a cross-sectional study
title_fullStr COVID-19 seroprevalence in Pakistan: a cross-sectional study
title_full_unstemmed COVID-19 seroprevalence in Pakistan: a cross-sectional study
title_short COVID-19 seroprevalence in Pakistan: a cross-sectional study
title_sort covid-19 seroprevalence in pakistan: a cross-sectional study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987211/
https://www.ncbi.nlm.nih.gov/pubmed/35387815
http://dx.doi.org/10.1136/bmjopen-2021-055381
work_keys_str_mv AT ahmadahsanm covid19seroprevalenceinpakistanacrosssectionalstudy
AT shahzadkhurram covid19seroprevalenceinpakistanacrosssectionalstudy
AT masoodmariumn covid19seroprevalenceinpakistanacrosssectionalstudy
AT umarmaida covid19seroprevalenceinpakistanacrosssectionalstudy
AT abbasifahad covid19seroprevalenceinpakistanacrosssectionalstudy
AT hafeezassad covid19seroprevalenceinpakistanacrosssectionalstudy